, is part of the VISION trial which is led by an international group including researchers at The Institute of Cancer Research and The Royal Marsden, and the Memorial Sloan Kettering Cancer Center in the U.S.Prostate-specific membrane antigen, or PSMA, is a protein present at higher levels on the surface of cancer cells in some prostate cancer patients. Lu-PSMA seeks outwith high levels of PSMA, binds to them and delivers a precise dose of radiation to destroy the cancer.
The patients were asked to fill in three questionnaires which established scores for their quality of life the severity of pain and the impact of pain on daily functions and their current state of health across several areas of life.It took longer for patients' quality of life to worsen in the treatment group—9.7 months for the Lu-PSMA group compared with just 2.4 months for patients receiving standard care.
Measures for general state of health took 0.9 months to worsen for patients receiving Lu-PSMA compared with 0.4 months for patients receiving standard care.